miR-184 Biomarker Stratification for Pachychoroid Anti-VEGF Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pachychoroid spectrum diseases, such as central serous chorioretinopathy, lack definitive clinical trials and fail to distinguish patients who do not benefit from anti-VEGF therapy, necessitating a need for personalized treatment strategies.
Innovation Solution
A composition and method utilizing miR-184 as a biomarker for diagnosing and predicting the prognosis of pachychoroid spectrum diseases by measuring its expression levels in aqueous humor samples, aiding in determining therapeutic responsiveness to anti-VEGF therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-VEGF therapy is used to treat pachychoroid spectrum diseases, then subretinal fluid levels are reduced, but therapeutic responsiveness varies significantly among patients with no clear distinction of who benefits
Solution Approach 1:
The patent applies preliminary action by measuring miR-184 expression levels in aqueous humor before initiating anti-VEGF therapy to predict which patients will respond therapeutically. This pre-treatment biomarker assessment allows clinicians to anticipate treatment outcomes and avoid ineffective therapies, thereby resolving the contradiction between achieving fluid reduction and identifying responsive patients.
Solution Approach 2:
The patent introduces miR-184 expression level as an intermediary biomarker that mediates between the treatment intervention (anti-VEGF therapy) and the outcome (therapeutic responsiveness). This molecular mediator provides objective information to distinguish responsive from non-responsive patients, solving the information loss problem in patient stratification.
2Ease of operation
If standardized anti-VEGF treatment is applied to all pachychoroid spectrum disease patients, then treatment simplicity is maintained, but personalized treatment strategies cannot be implemented
Solution Approach 1:
The patent applies parameter changes by using miR-184 expression levels as a diagnostic parameter to stratify patients into responsive and non-responsive groups. This parameter-based approach enables personalized treatment selection (anti-VEGF for responsive patients, alternative therapies for non-responsive patients) while maintaining operational simplicity through a single biomarker test, thus resolving the contradiction between treatment simplicity and personalization.
3Reliability
If clinical trials are conducted to establish definitive treatment guidelines, then evidence-based medicine is improved, but time and resource consumption increase significantly
Solution Approach 1:
The patent applies preliminary action by establishing miR-184 as a predictive biomarker through preliminary research, which can then be used immediately in clinical practice to guide treatment decisions. This eliminates the need for lengthy prospective clinical trials to determine treatment responsiveness, as the biomarker provides immediate predictive information, thereby reducing time loss while maintaining evidence-based reliability.
Data Source
Figure 1a
Figure 1b
Figure 1c
AI summary
The present invention relates to a composition and a kit for diagnosis or prognosis prediction of pachychoroid spectrum disease, and a method for predicting therapeutic responsiveness to pachychoroid spectrum disease.